- Report
- September 2023
- 170 Pages
Global
From €4632EUR$4,799USD£3,973GBP
- Report
- February 2024
- 202 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- January 2024
- 213 Pages
Global
From €5309EUR$5,500USD£4,554GBP
- Report
- March 2024
- 194 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- March 2024
- 181 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- November 2023
- 215 Pages
Global
From €4766EUR$5,111USD£3,950GBP
- Report
- July 2023
- 180 Pages
Global
From €5743EUR$5,950USD£4,926GBP
- Report
- February 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- January 2024
- 150 Pages
Global
From €4681EUR$4,850USD£4,016GBP
- Report
- April 2024
- 762 Pages
Global
From €5598EUR$5,800USD£4,802GBP
- Report
- April 2024
- 334 Pages
Global
From €5405EUR$5,600USD£4,637GBP
- Report
- November 2023
- 139 Pages
Global
From €2412EUR$2,499USD£2,069GBP
- Report
- February 2024
- 173 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- February 2024
- 159 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- February 2024
- 187 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- April 2024
- 30 Pages
Global
From €3137EUR$3,250USD£2,691GBP
- Report
- January 2024
- 185 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- November 2023
- 190 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- November 2023
- 185 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- October 2023
- 188 Pages
Global
From €4729EUR$4,900USD£4,057GBP
The RNA Vaccine market is a subset of the larger Vaccine market, which is composed of products designed to prevent and treat infectious diseases. RNA Vaccines are a relatively new type of vaccine, which use genetic material to stimulate an immune response. This type of vaccine is particularly attractive due to its potential to be quickly developed and manufactured, as well as its ability to target a wide range of diseases.
RNA Vaccines are being developed for a variety of diseases, including influenza, malaria, and cancer. These vaccines are being studied in clinical trials, and some have already been approved for use in humans.
The RNA Vaccine market is expected to grow in the coming years, as more vaccines are developed and approved. This growth is driven by the increasing demand for vaccines, as well as the potential for RNA Vaccines to be used to treat a wide range of diseases.
Some companies in the RNA Vaccine market include Moderna, Inovio Pharmaceuticals, CureVac, and Arcturus Therapeutics. Show Less Read more